Lazard Places 'Buy' Rating on Sequenom Stock | GenomeWeb
NEW YORK (GenomeWeb News) – Investment firm Lazard Capital today initiated coverage of Sequenom’s stock with a “Buy” rating and a price target of $20.
 
Sequenom’s shares were trading up 3.2 percent at $7.79 in early Friday trading on the Nasdaq.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.